Background: Radiotherapy with or without concurrent chemotherapy forms the mainstay of treatment of head and neck cancers. Oral mucositis is one of the most common complications of Chemo Radio-Therapy(CRT) which outweighs the systemic complaints both in terms of severity and difficulty in management. The aim of our study was to assess the role of oral glutamine supplementation in prevention of oral mucositis in patients receiving CRT to the head and neck. Methods: This was a Prospective Randomized study performed between April 2017 to November 2017.Total 60 patients (30 in each arm) were enrolled. Patients in ARM A were advised to take Glutamine crystalline powder dissolved in water to be consumed daily within 1 hour before radiation and were again asked to repeat the same dose 7 to 8 hours post radiation. Glutamine Treatment was 5 days/week on Radio-therapy days only. Patients in ARM B were given Placebo twice a day in same fashion as ARM A.Weekly Cisplatin was given in both arms. Results: Average no of days for onset of mucositis in glutamine arm was 17 days vs 32 days in control arm. 26.67% of patients in the glutamine arm developed mucositis in the 5th to 6th week, whereas 60% patients in the control arm developed mucositis as early as the 3rd week. 13% of the patients in the glutamine arm developed G3 mucositis whereas 23.3% of patients in the control arm developed G3 mucositis. 46.6% percent of patients in the glutamine arm received complete six cycles of chemotherapy, whereas only 13.33% of the patients in the control arm could complete six cycles of chemotherapy(p<0.001) 93.3% of patients in the glutamine arm completed treatment within the stipulated period of 7 weeks, whereas only 33.3% patients in the control arm completed treatment within 7 weeks.(p<0.05). Conclusion: Glutamine significantly decreases the onset as well as the severity of mucositis in patients receiving CRT to the head and neck thus translating into lesser treatment gaps and improvement in patient quality of life.

Malignant melanoma is a rare cancer, its incidence being 1% of all cancers. Malignant melanoma of the female genital tract is even rarer with incidence of 3% to 7% of all malignant melanomas. It usually occurs in postmenopausal women. We present a case of malignant melanoma of the uterine cervix in a multiparous premenopausal 29 year old female. She underwent a modified radical hysterectomy. She was stage III and was treated with external beam radiotherapy to the pelvis followed by brachytherapy. Since then the patient was on regular follow up until she developed lung metastasis. Malignant melanoma of the cervix has very less data in literature. Through this case report we will emphasize on the role of radiotherapy in malignant melanoma of uterine cervix

Melanomas affecting the small bowel are usually metastasis from primary cutaneous lesions. A primary melanoma of the gastrointestinal tract is very rare with reported incidence of just 3%. We present a case of small bowel melanoma with liver metastases. Primary malignant melanoma of the small intestine is quite rare with only a few cases reported in literature. Like its cutaneous counterpart, intestinal melanomas too remains an aggressive disease with a poor prognosis. The overall survival of malignant melanoma affecting the GI tract is 4 to 6 months with a survival rate of less than 10% at 5 years.